keyword
MENU ▼
Read by QxMD icon Read
search

chronic C hepatitis

keyword
https://www.readbyqxmd.com/read/28449343/cost-effectiveness-of-the-highly-effective-direct-acting-antivirals-in-the-treatment-of-chronic-hepatitis-c-in-hong-kong
#1
Angeline Oi-Shan Lo, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
BACKGROUND AND AIM: In Asia-Pacific where cost is a major concern, peginterferon plus ribavirin (PR) often remain as the standard of care in chronic hepatitis C (CHC) treatment, while the direct-acting antivirals (DAAs) are commonly recommended as retreatment. Newer DAAs can achieve a sustained virological response (SVR) of nearly 100% with pan-genotypic coverage, that is "Highly Effective DAAs." We aimed to investigate the most desirable cost range for the Highly Effective DAAs using Hong Kong as an example...
May 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28449272/adalimumab-is-a-safe-option-for-psoriasis-patients-with-concomitant-hepatitis-b-or-c-infection-a-multicentre-cohort-study-of-37-patients-and-review-of-the-literature-%C3%A2-reply-to-dr-ricceri-letter
#2
Stefano Piaserico
We thank Ricceri et al. for their comments (1) and interest in our study (2). Despite the recent advances in prevention and treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, these two chronic infections still represent the most common cause of chronic liver disease. Dermatologists are frequently encountering patients with psoriatic disease who have concomitant HBV or HCV infection in daily clinical practice. Dr Ricceri provided in his letter further long-term follow-up data (60 months) on the use of etanercept or adalimumab in 17 psoriatic patients affected by past HBV infection or chronic HCV infection...
April 27, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28449246/review-article-hepatitis-e-a-concise-review-of-virology-epidemiology-clinical-presentation-and-therapy
#3
REVIEW
M C Donnelly, L Scobie, C L Crossan, H Dalton, P C Hayes, K J Simpson
BACKGROUND: Hepatitis E virus (HEV) is a leading cause of acute icteric hepatitis and acute liver failure in the developing world. During the last decade, there has been increasing recognition of autochthonous (locally acquired) HEV infection in developed countries. Chronic HEV infection is now recognised, and in transplant recipients this may lead to cirrhosis and organ failure. AIM: To detail current understanding of the molecular biology of HEV, diagnostic and therapeutic strategies and propose future directions for basic science and clinical research...
April 27, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28449189/reply-adalimumab-is-a-safe-option-for-psoriasis-patients-with-concomitant-hepatitis-b-or-c-infection-a-multicentre-cohort-study-of-37-patients-and-review-of-the-literature
#4
F Ricceri, L Pescitelli, L Lazzeri, A Di Cesare, F Prignano
We have read with interest the article by Piaserico et al. concerning the use of tumour necrosis factor-alpha (TNF-alpha) blocking agent adalimumab in psoriatic patients with concomitant hepatitis B virus (HBV) or hepatitis C virus (HCV). The authors describe 17 psoriatic patients affected by chronic HBV infection and 20 affected by chronic HCV who were successfully treated with adalimumab with no evidence of HBV or HCV reactivation in a mean follow-up period of 27 and 40 months, respectively. We have previously described our successful experience of treatment with anti-TNF-alpha therapy in 17 psoriatic patients (11 with past HBV infection, 5 with chronic HCV infection and one affected by both HBV and HCV) without the use of lamivudine or adenofovir, and can now report on long-term follow-up data (mean follow-up period of 60 months)...
April 27, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28449115/estimation-of-state-level-prevalence-of-hepatitis-c-virus-infection-us-states-and-district-of-columbia-2010
#5
Eli S Rosenberg, Eric W Hall, Patrick S Sullivan, Travis H Sanchez, Kimberly A Workowski, John W Ward, Deborah Holtzman
Background.: Hepatitis C virus (HCV) infection is the most common chronic blood-borne infection in the United States and a leading cause of morbidity and mortality. Previous analyses of the US National Health and Nutrition Examination Survey (NHANES) indicated approximately 3.6 million noninstitutionalized persons with antibody to HCV (anti-HCV). However, state-level prevalence remains less understood and cannot be estimated reliably from NHANES alone. Methods.: We used 3 publicly available government data sources to estimate anti-HCV prevalence in each US state among noninstitutionalized persons aged ≥18 years...
April 26, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28448999/outcome-of-all-oral-direct-acting-antiviral-regimens-on-the-rate-of-development-of-hepatocellular-carcinoma-in-patients-with-hepatitis-c-virus-genotype-1-related-chronic-liver-disease
#6
Fumihiro Ogata, Masahiro Kobayashi, Norio Akuta, Mitutaka Osawa, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Fumitaka Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
OBJECTIVES: There is little information on the risk factors for hepatocellular carcinoma (HCC) and outcome of treatment with an all-oral combination of direct-acting antiviral regimens following eradication of hepatitis C virus (HCV) RNA. METHODS: The study subjects were 1,170 patients with HCV genotype 1-related chronic liver disease treated with either NS5A inhibitor plus NS3/4A protease inhibitor (n = 707), NS5A inhibitor plus NS5B polymerase inhibitor (n = 345), or NS5A inhibitor, NS3/4A protease inhibitor plus ritonavir (n = 118), for 12-24 weeks...
April 28, 2017: Oncology
https://www.readbyqxmd.com/read/28448576/management-of-chronic-hepatitis-c-at-a-primary-health-clinic-in-the-high-burden-context-of-karachi-pakistan
#7
Yuely A Capileno, Rafael Van den Bergh, Dmytro Donchunk, Sven Gudmund Hinderaker, Saeed Hamid, Rosa Auat, Gul Ghuttai Khalid, Razia Fatima, Aashifa Yaqoob, Catherine Van Overloop
BACKGROUND: The burden of hepatitis C (HCV) infection in Pakistan is among the highest in the world, with a reported national HCV prevalence of 6.7% in 2014. In specific populations, such as in urban communities in Karachi, the prevalence is suspected to be higher. Interferon-free treatment for chronic HCV infection (CHC) could allow scale up, simplification and decentralization of treatment to such communities. We present an interim analysis over the course of February-December 2015 of an interferon-free, decentralised CHC programme in the community clinic in Machar Colony, Karachi, Pakistan...
2017: PloS One
https://www.readbyqxmd.com/read/28447580/liver-enzyme-normalization-predicts-success-of-hepatitis-c-oral-direct-acting-antiviral-treatment
#8
Sarwat T Khan, Michaeline McGuinty, Daniel J Corsi, Curtis L Cooper
PURPOSE: Monitoring of hepatitis C virus (HCV) treatment response is performed by serial HCV RNA measurements; however, this may not be useful for predicting treatment success or failure with oral direct-acting antiviral agent (DAA) therapies. Liver enzyme levels, which are elevated in chronic HCV and tend to decline on therapy, may serve as a more logistically and economically feasible alternative for monitoring treatment response. SOURCE: The Ottawa Hospital Viral Hepatitis Clinic patients (n=219), receiving interferon-free oral DAA treatments, were assessed for liver enzymes and HCV RNA levels at baseline, week 4 and ≥12 weeks post-treatment...
April 26, 2017: Clinical and Investigative Medicine. Médecine Clinique et Experimentale
https://www.readbyqxmd.com/read/28447325/interferon-free-therapy-with-sofosbuvir-plus-ribavirin-for-successful-treatment-of-genotype-2-hepatitis-c-virus-with-lichen-planus-a-case-report
#9
Ayumu Yoshikawa, Katsumi Terashita, Kenichi Morikawa, Soichiro Matsuda, Takahiro Yamamura, Koichiro Sarashina, Shintaro Nakano, Yoshimitsu Kobayashi, Susumu Sogabe, Kazuhiro Takahashi, Shin Haba, Hisashi Oda, Tatsuro Takahashi, Takuto Miyagishima, Naoya Sakamoto
Hepatitis C virus (HCV) infection remains the main cause of liver disease and can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV may also develop extrahepatic manifestations in the skin, eyes, joints, kidneys, nervous system, and immune system. In fact, several studies reported that up to 70% of HCV patients experienced extrahepatic manifestations. Lichen planus (LP), which is an immune system disorder that is triggered by viral infections, allergens, and stress, can affect the skin, mouth, nails, and scalp...
April 26, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28447238/effects-of-hepatitis-c-virus-infection-on-the-safety-of-chemotherapy-for-breast-cancer-patients
#10
Yu Liu, Zhan-Yi Li, Jia-Ni Wang, Xi Li, Qun-Ai Huang, Yong Huang
PURPOSE: Hepatitis C virus (HCV) is one of the major pathogens of chronic viral hepatitis, and approximately 38 million patients are infected with HCV in China. However, little information is available on the effect of HCV infection during chemotherapy for breast cancer and the impact of HCV infection on the toxicity of chemotherapy and targeted therapy. METHODS: We performed a retrospective survey of 835 patients who were diagnosed with breast cancer between January 2010 and December 2015 at our institution...
April 26, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28447075/sofosbuvir-velpatasvir-fixed-dose-combination-for-the-treatment-of-chronic-hepatitis-c-virus-infection
#11
V Nehra, S A Rizza, Z Temesgen
The fixed-dose combination of sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor, and velpatasvir, a second-generation NS5A inhibitor, has been approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection. This combination, administered over 12 weeks as a single-tablet regimen, has resulted in high cure rates in all 6 HCV genotypes and in a variety of patient populations, including patients without cirrhosis, patients with compensated cirrhosis and patients with HIV coinfection...
March 2017: Drugs of Today
https://www.readbyqxmd.com/read/28446674/broadening-cd4-and-cd8-t-cell-responses-against-hepatitis-c-virus-by-vaccination-with-ns3-overlapping-peptide-panels-in-cross-priming-liposomes
#12
Jonathan Filskov, Marianne Mikkelsen, Paul R Hansen, Jan P Christensen, Allan R Thomsen, Peter Andersen, Jens Bukh, Else Marie Agger
Despite the introduction of effective drugs to treat patients with chronic hepatitis C virus (HCV) infection, a vaccine would be the only means to substantially reduce the worldwide disease burden. An incomplete understanding of how HCV interacts with its human host and evades immune surveillance has hampered vaccine development. It is generally accepted that in infected individuals, a narrow repertoire of exhausted T cells is a hallmark of persistent infection, whereas broad vigorous CD4(+) and CD8(+) T cell responses are associated with control of acute hepatitis C...
April 26, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28445322/validation-of-prognostic-scores-to-predict-short-term-mortality-in-patients-with-hbv-related-acute-on-chronic-liver-failure-the-clif-c-of-is-superior-to-meld-clif-sofa-and-clif-c-aclf
#13
Ning Li, Chong Huang, Kang-Kang Yu, Qing Lu, Guang-Feng Shi, Jian-Ming Zheng
Acute-on-chronic liver failure (ACLF) in chronic hepatitis B (CHB) patients has a high short-term mortality. Identification of effective models to predict the short-term mortality may enable early intervention and improve patients' prognosis. We aim to assess the performance of the CLIF Consortium Organ Failure score (CLIF-C OFs), CLIF sequential organ failure assessment score (CLIF-SOFAs), CLIF Consortium ACLF score (CLIF-C ACLFs), ACLF grade, and model for end-stage liver disease score (MELDs) in predicting the short-term mortality in CHB patients with ACLF...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28445251/long-term-follow-up-of-patients-with-chronic-hepatitis-c-treated-with-%C3%AE-interferon-and-ribavirin-antiviral-therapy-clinical-and-fibrosis-impact-of-treatment-response
#14
Patricia Cordero-Ruiz, Isabel Carmona-Soria, Manuel Rodríguez-Téllez, Angel Caunedo-Alvarez, Roberto H Quezada-Pacheco, Alexander Flores-Cucho, Manuel Romero-Gómez, Ángel Vilches-Arenas
BACKGROUND AND GOALS: The slow progression of chronic hepatitis C (CHC) infection requires long observation periods to detect clinical changes. We compare the incidence of clinical events, hepatocellular carcinoma (HCC), overall mortality, liver-related mortality, and fibrosis progression between patients with a sustained virological response (SVR) and nonresponders (NR) after a 13-year follow-up period. STUDY: One hundred and eighty-two CHC patients, who received interferon and ribavirin treatment between 1996 and 2000, were included...
April 25, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28444987/platelet-count-spleen-length-and-platelet-count-to-spleen-length-ratio-for-the-diagnosis-of-oesophageal-varices-in-people-with-chronic-liver-disease-or-portal-vein-thrombosis
#15
REVIEW
Agostino Colli, Juan Cristóbal Gana, Jason Yap, Thomasin Adams-Webber, Natalie Rashkovan, Simon C Ling, Giovanni Casazza
BACKGROUND: Current guidelines recommend screening of people with oesophageal varices via oesophago-gastro-duodenoscopy at the time of diagnosis of hepatic cirrhosis. This requires that people repeatedly undergo unpleasant invasive procedures with their attendant risks, although half of these people have no identifiable oesophageal varices 10 years after the initial diagnosis of cirrhosis. Platelet count, spleen length, and platelet count-to-spleen length ratio are non-invasive tests proposed as triage tests for the diagnosis of oesophageal varices...
April 26, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28444420/periportal-lymphatic-system-on-post-hepatobiliary-phase-gd-eob-dtpa-enhanced-mr-imaging-in-normal-subjects-and-patients-with-chronic-hepatitis-c
#16
Yasunari Yamada, Shunro Matsumoto, Hiromu Mori, Ryo Takaji, Maki Kiyonaga, Naoki Hijiya, Rika Tanoue, Kenichiro Tomonari, Shuichi Tanoue, Norio Hongo, Masayuki Ohta, Masataka Seike, Masafumi Inomata, Kazunari Murakami, Masatsugu Moriyama
PURPOSE: We sought to evaluate visualization of periportal lymphatics and lymph nodes (lymphatic system) on Gd-EOB-DTPA-enhanced magnetic resonance (MR) images using a fat-suppressed T2-weighted sequence with 3-dimensional (3D) volume isotropic turbo spin echo acquisition (VISTA) at 3.0 T in normal subjects and patients with chronic hepatitis C. METHODS: MR imaging was performed in 254 subjects between June 2013 and May 2016. After applying inclusion and exclusion criteria, the final population was 31 normal subjects and 34 patients with chronic hepatitis C...
April 25, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28443566/atypical-chemokine-receptor-1-polymorphism-can-not-affect-susceptibility-to-hepatitis-c-virus
#17
Shu Ting Zhang, Ming Shi, Lin Nan Shao, Shi Hang Zhou, Wei Jian Yu, Mei Chen, Nan Xiao, Ying Duan, Ling Zi Pan, Ni Wang, Wen Qian Song, Yue Xin Xia, Li Zhang, Ning Qi, Ming Liu
BACKGROUND: Hepatitis C virus (HCV) has infected 130 to 150 million individuals globally. A significant number of chronically infected patients will develop liver cirrhosis, hepatocellular cancer and liver failure. Atypical Chemokine Receptor 1 (ACKR1) has become the focus because of its diverse roles in diseases. However, little is known regarding the association of ACKR1 polymorphism with the susceptibility to HCV. AIMS: The purpose of the present study is to determine the association of the ACKR1 polymorphisms (rs12075) with HCV susceptibility...
April 6, 2017: Balkan Medical Journal
https://www.readbyqxmd.com/read/28442915/efficacy-and-safety-outcomes-of-sofosbuvir-based-treatment-regimens-for-hepatitis-c-virus-infected-patients-with-or-without-cirrhosis-from-phase-iii-clinical-trials
#18
REVIEW
Young-Mo Yang, Eun Joo Choi
BACKGROUND: With the appearance of oral direct-acting antivirals (DAAs), the field of hepatitis C virus (HCV) treatment has been dramatically changed. This evolution makes possible for all oral treatments to be available for the treatment of HCV-infected patients. The aims of this review were to report the efficacy and safety of sofosbuvir (SOF)-based regimens for the treatment of patients with chronic HCV infection and to provide our clinical perspectives on these regimens. METHODS: A literature search of clinical studies published in PubMed and posted on ClinicalTrials...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28442794/innate-and-adaptive-immunity-shape-circulating-hcv-strains
#19
Silvana Gaudieri, Michaela Lucas
An unbiased genome-to-genome analysis in chronic hepatitis C virus (HCV) infection confirms the innate and adaptive arms of the immune system as drivers of viral evolution. Viral adaptation has a critical role in the interaction between host and pathogen and has important clinical implications for infection outcome.
April 26, 2017: Nature Genetics
https://www.readbyqxmd.com/read/28442604/hepatitis-c-virus-indirectly-disrupts-dna-damage-induced-p53-responses-by-activating-protein-kinase-r
#20
Jonathan K Mitchell, Bentley R Midkiff, Benjamin Israelow, Matthew J Evans, Robert E Lanford, Christopher M Walker, Stanley M Lemon, David R McGivern
Many DNA tumor viruses promote cellular transformation by inactivating the critically important tumor suppressor protein p53. In contrast, it is not known whether p53 function is disrupted by hepatitis C virus (HCV), a unique, oncogenic RNA virus that is the leading infectious cause of liver cancer in many regions of the world. Here we show that HCV-permissive, liver-derived HepG2 cells engineered to constitutively express microRNA-122 (HepG2/miR-122 cells) have normal p53-mediated responses to DNA damage and that HCV replication in these cells potently suppresses p53 responses to etoposide, an inducer of DNA damage, or nutlin-3, an inhibitor of p53 degradation pathways...
April 25, 2017: MBio
keyword
keyword
63050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"